Preclinical absorption, distribution, metabolism, excretion, and pharmacokinetic–pharmacodynamic modelling of N-(4-(3-((3S,4R)-1-ethyl-3-fluoropiperidine-4-ylamino)-1H-pyrazolo[3,4-b]pyridin-4-yloxy)-3-fluorophenyl)-2-(4-fluorophenyl)-3-oxo-2,3-dihydropyridazine-4-carboxamide, a novel MET kinase inhibitor

References

• Bang Y, Kawk EL, Shaw AT, Camidge DR, Iafrate AJ, Maki RG, Solomon BJ, Ou SI, Salgia R, Clark JW. (2010). Clinical Activity of the Oral ALK Inhibitor PF-02341066 in ALK-Positive Patients with Non-Small Cell Lung Cancer (NSCLC). 2010 ASCO Annual Meeting.
   Google Scholar
• Birchmeier C, Birchmeier W, Gherardi E, Vande Woude GF. (2003). Met, metastasis, motility and more. Nat Rev Mol Cell Biol 4:915–925.
   PubMed Web of Science ®Google Scholar
• Boxenbaum H. (1982). Interspecies scaling, allometry, physiological time, and the ground plan of pharmacokinetics. J Pharmacokinet Biopharm 10:201–227.
   PubMedGoogle Scholar
• Cui JJ. (2007). Inhibitors targeting hepatocyte growth factor receptor and their potential therapeutic applications. Expert Opin Ther Pat 17:1035–1045.
   Web of Science ®Google Scholar
• Davies B, Morris T. (1993). Physiological parameters in laboratory animals and humans. Pharm Res 10:1093–1095.
   PubMed Web of Science ®Google Scholar
• Di Renzo MF, Olivero M, Giacomini A, Porte H, Chastre E, Mirossay L, Nordlinger B, Bretti S, Bottardi S, Giordano S. (1995). Overexpression and amplification of the met/HGF receptor gene during the progression of colorectal cancer. Clin Cancer Res 1:147–154.
   PubMed Web of Science ®Google Scholar
• Eder JP, Vande Woude GF, Boerner SA, LoRusso PM. (2009). Novel therapeutic inhibitors of the c-Met signaling pathway in cancer. Clin Cancer Res 15:2207–2214.
   PubMed Web of Science ®Google Scholar
• Engelman JA, Zejnullahu K, Mitsudomi T, Song Y, Hyland C, Park JO, Lindeman N, Gale CM, Zhao X, Christensen J, Kosaka T, Holmes AJ, Rogers AM, Cappuzzo F, Mok T, Lee C, Johnson BE, Cantley LC, Jänne PA. (2007). MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 316:1039–1043.
   PubMed Web of Science ®Google Scholar
• Feng MR, Lou X, Brown RR, Hutchaleelaha A. (2000). Allometric pharmacokinetic scaling: towards the prediction of human oral pharmacokinetics. Pharm Res 17:410–418.
   PubMed Web of Science ®Google Scholar
• Garcia A, Cunningham CC, Nemunaitis J, Li C, Rulewski N, Dovholuk A, Savage R, Chan T, Bukowksi R, Mekhail T. (2007). Phase 1 Study of ARQ 197, A Selective Inhibitor of the c-Met RTK in Patients with Metastatic Solid Tumors Reaches Recommended Phase 2 dose. 2007 ASCO Annual Meeting.
   Google Scholar
• Gupta A, Karakiewicz PI, Roehrborn CG, Lotan Y, Zlotta AR, Shariat SF. (2008). Predictive value of plasma hepatocyte growth factor/scatter factor levels in patients with clinically localized prostate cancer. Clin Cancer Res 14:7385–7390.
   PubMed Web of Science ®Google Scholar
• Kammula US, Kuntz EJ, Francone TD, Zeng Z, Shia J, Landmann RG, Paty PB, Weiser MR. (2007). Molecular co-expression of the c-Met oncogene and hepatocyte growth factor in primary colon cancer predicts tumor stage and clinical outcome. Cancer Lett 248:219–228.
   PubMed Web of Science ®Google Scholar
• Lee JH, Han SU, Cho H, Jennings B, Gerrard B, Dean M, Schmidt L, Zbar B, Vande Woude GF. (2000). A novel germ line juxtamembrane Met mutation in human gastric cancer. Oncogene 19:4947–4953.
   PubMed Web of Science ®Google Scholar
• Lengyel E, Prechtel D, Resau JH, Gauger K, Welk A, Lindemann K, Salanti G, Richter T, Knudsen B, Vande Woude GF, Harbeck N. (2005). C-Met overexpression in node-positive breast cancer identifies patients with poor clinical outcome independent of Her2/neu. Int J Cancer 113:678–682.
   PubMed Web of Science ®Google Scholar
• Lin JH, Yamazaki M. (2003). Clinical relevance of P-glycoprotein in drug therapy. Drug Metab Rev 35:417–454.
   PubMed Web of Science ®Google Scholar
• Liu X, Newton RC, Scherle PA. (2010). Developing c-MET pathway inhibitors for cancer therapy: progress and challenges. Trends Mol Med 16:37–45.
   PubMed Web of Science ®Google Scholar
• Liu X, Yao W, Newton RC, Scherle PA. (2008). Targeting the c-MET signaling pathway for cancer therapy. Expert Opin Investig Drugs 17:997–1011.
   PubMed Web of Science ®Google Scholar
• Ma PC, Maulik G, Christensen J, Salgia R. (2003). c-Met: structure, functions and potential for therapeutic inhibition. Cancer Metastasis Rev 22:309–325.
   PubMed Web of Science ®Google Scholar
• Ma WW, Adjei AA. (2009). Novel agents on the horizon for cancer therapy. CA Cancer J Clin 59:111–137.
   PubMed Web of Science ®Google Scholar
• Mager DE, Wyska E, Jusko WJ. (2003). Diversity of mechanism-based pharmacodynamic models. Drug Metab Dispos 31:510–518.
   PubMed Web of Science ®Google Scholar
• Mahmood I. (2005). Important Considerations for the Prediction of Clearance of Animals to Humans. Interspecies Pharmacokinetic Scaling. Rockville: Pine House Publishers, pp. 72–74.
   Google Scholar
• Mahmood I, Balian JD. (1996). Interspecies scaling: predicting clearance of drugs in humans. Three different approaches. Xenobiotica 26:887–895.
   PubMed Web of Science ®Google Scholar
• Maulik G, Kijima T, Ma PC, Ghosh SK, Lin J, Shapiro GI, Schaefer E, Tibaldi E, Johnson BE, Salgia R. (2002). Modulation of the c-Met/hepatocyte growth factor pathway in small cell lung cancer. Clin Cancer Res 8:620–627.
   PubMed Web of Science ®Google Scholar
• McDermott U, Sharma SV, Dowell L, Greninger P, Montagut C, Lamb J, Archibald H, Raudales R, Tam A, Lee D, Rothenberg SM, Supko JG, Sordella R, Ulkus LE, Iafrate AJ, Maheswaran S, Njauw CN, Tsao H, Drew L, Hanke JH, Ma XJ, Erlander MG, Gray NS, Haber DA, Settleman J. (2007). Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling. Proc Natl Acad Sci USA 104:19936–19941.
   PubMed Web of Science ®Google Scholar
• Mekhail T, Rich T, Rosen L, Chai F, Semic-Suka Z, Savage RE, Senzer N. (2009). Final Results: A Dose Escalation Phase I Study of ARQ 197, A Selective c-Met Inhibitor, in Patients with Metastatic Solid Tumors. 2009 ASCO Annual Meeting.
   Google Scholar
• Mineo R, Costantino A, Frasca F, Sciacca L, Russo S, Vigneri R, Belfiore A. (2004). Activation of the hepatocyte growth factor (HGF)-Met system in papillary thyroid cancer: biological effects of HGF in thyroid cancer cells depend on Met expression levels. Endocrinology 145:4355–4365.
   PubMed Web of Science ®Google Scholar
• Miyata Y, Sagara Y, Kanda S, Hayashi T, Kanetake H. (2009). Phosphorylated hepatocyte growth factor receptor/c-Met is associated with tumor growth and prognosis in patients with bladder cancer: correlation with matrix metalloproteinase-2 and -7 and E-cadherin. Hum Pathol 40:496–504.
   PubMed Web of Science ®Google Scholar
• Peruzzi B, Bottaro DP. (2006). Targeting the c-Met signaling pathway in cancer. Clin Cancer Res 12:3657–3660.
   PubMed Web of Science ®Google Scholar
• Ponzo MG, Lesurf R, Petkiewicz S, O’Malley FP, Pinnaduwage D, Andrulis IL, Bull SB, Chughtai N, Zuo D, Souleimanova M, Germain D, Omeroglu A, Cardiff RD, Hallett M, Park M. (2009). Met induces mammary tumors with diverse histologies and is associated with poor outcome and human basal breast cancer. Proc Natl Acad Sci USA 106:12903–12908.
   PubMed Web of Science ®Google Scholar
• Porter J. (2010). Small molecule c-Met kinase inhibitors: a review of recent patents. Expert Opin Ther Pat 20:159–177.
   PubMed Web of Science ®Google Scholar
• Seiwert TY, Jagadeeswaran R, Faoro L, Janamanchi V, Nallasura V, El Dinali M, Yala S, Kanteti R, Cohen EE, Lingen MW, Martin L, Krishnaswamy S, Klein-Szanto A, Christensen JG, Vokes EE, Salgia R. (2009). The MET receptor tyrosine kinase is a potential novel therapeutic target for head and neck squamous cell carcinoma. Cancer Res 69:3021–3031.
   PubMed Web of Science ®Google Scholar
• Stella MC, Comoglio PM. (1999). HGF: a multifunctional growth factor controlling cell scattering. Int J Biochem Cell Biol 31:1357–1362.
   PubMed Web of Science ®Google Scholar
• Wakelee HA, Gettinger SN, Engelman JA, Janne PA, West HJ, Subramaniam DS, Leach JW, Wax MB, Yaron Y, Lara P Jr. (2010). A Phase Ib/II Study of XL184 (BMS 907351) with and without Erlotinib (E) in Patients (pts) with Non-Small Cell Lung Cancer (NSCLC). 2010 ASCO Annual Meeting.
   Google Scholar
• Yu S, Li S, Yang H, Lee F, Wu JT, Qian MG. (2005). A novel liquid chromatography/tandem mass spectrometry based depletion method for measuring red blood cell partitioning of pharmaceutical compounds in drug discovery. Rapid Commun Mass Spectrom 19:250–254.
   PubMed Web of Science ®Google Scholar